乳腺癌治疗研究进展

doi:10.3981/j.issn.1000-7857.2014.26.002

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1285 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要乳腺癌为女性发病率最高的恶性肿瘤，是严重影响女性身心健康的重要疾病。近年来，乳腺癌的治疗取得长足进步，在早期乳腺癌的保留乳房和保腋窝治疗等方面获得里程碑式的突破。本文综述不同病期乳腺癌治疗的最新进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李金锋

关键词 ：乳腺癌, 保乳, 前哨淋巴结, 转移, 治疗

Abstract：Breast cancer is the highest incidence of malignant disease in women and seriously affects their health physically and mentally. We have achieved great progress in treatment of breast cancer in recent years, expecially in some aspects such as breastconserving therapy and axillary-conserving treatment. The latest advancement of treatments in early and late stages of breast cancer is summarized.

Key words： breast cancer breast-conserving sentinel node metastasis treatment

收稿日期: 2014-08-12

ZTFLH:

R737.9

作者简介: 李金锋，主任医师，研究方向为乳腺癌治疗，电子信箱：jinfengliabc@163.com

引用本文:

李金锋. 乳腺癌治疗研究进展[J]. 科技导报, 2014, 32(26): 22-26.
LI Jinfeng. Research Progress in Breast Cancer Treatment. journal1, 2014, 32(26): 22-26.

链接本文:

http://www.kjdb.org/CN/10.3981/j.issn.1000-7857.2014.26.002 或 http://www.kjdb.org/CN/Y2014/V32/I26/22

[1] Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primarybreast cancer[J]. Cancer, 1977, 40(S1): 574-587.
[2] Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trails[J]. New England Journal of Medicine, 1995, 333(22): 1444-1455.
[3] Reintgen C, Reintgen D, Solin L J. Advances in local-regional treatment for patients with early- stage breast cancer: A review of the field[J]. Clinical Breast Cancer, 2010, 10(3): 180-187.
[4] 王立泽, 欧阳涛, 王天峰, 等. 乳腺癌保乳治疗后局部复发的临床研究[J]. 中华外科杂志, 2010, 48(24): 1851-1854. Wang Lize, Ouyang Tao, Wang Tianfeng, et al. Clinical research on local relapses after breast conserving therapy of breast cancer[J]. Chinese Journal of Surgery, 2010, 48(24): 1851-1854.
[5] Fortin A, Larochelle M, Laverdiere J, et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy[J]. Journal of Clinical Oncology, 1999, 17(1): 101-109.
[6] Khan S A, Eladoumikdachi F. Optimal Surgical treatment of breast cancer: Implications for local control and survival[J]. Journal of Surgical Oncology, 2010, 101(8): 677-686.
[7] Fisher B, Anderson S, Bryant J, et al. Twenty- year follow- up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. New England Journal of Medicine, 2002, 347(16): 1233-1241.
[8] Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast- conserving surgery with radical mastectomy for early breast cancer[J]. New England Journal of Medicine, 2002, 347(16): 1227-1232.
[9] Litière S, Werutsky G, Fentiman I S, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial[J]. Lancet Oncology, 2012, 13(4): 412-419.
[10] Katipamula R, Degnim A C, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: Eeffect of surgical year and preoperative magnetic resonance imaging[J]. Journal of Clinical Oncology, 2009, 27(25): 4082-4088.
[11] Plana M N, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: Systematic review of diagnostic accuracy and meta- analysis[J]. European Radiology, 2012, 22(1): 26-38.
[12] Solin L J, Orel S G, Hwang W T, et al. Relationship of breast magnetic resonance imaging to outcome after breast- conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ[J]. Journal of Clinical Oncology, 2008, 26(3): 386-391.
[13] Moran M S, Schnitt S J, Giuliano A E, et al. Society of Surgical Oncology American Society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages i and ii invasive breast cancer[J]. International Journal of Radiation Oncology, Biology, Physics, 2014, 88(3): 553- 564.
[14] Petrek J A, Senie R T, Peters M, et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis[J]. Cancer, 2001, 92(6): 1368-1377.
[15] Krag D N, Weaver D L, Alex J C, et al. Surgical resection and radiolocalization of the sentinal lymph node in breast cancer using a gamma probe[J]. Surgical Oncology, 1993, 2(6): 335-339.
[16] Mansel R E, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial[J]. Journal of the National Cancer Institute , 2006, 98(9): 599-609.
[17] Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer[J]. New England Journal of Medicine, 2003, 349(6): 546-553.
[18] Krag D N, Anderson S J, Julian T B,et al. Sentinel- lymph- node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncology, 2010, 11(10): 927–933.
[19] Giuliano A E, Hunt K K, Ballman K V, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis[J]. Journal of the American Medical Association, 2011, 305(6): 569–575.
[20] Goldhirsch A，Wood W C, Coates A S, et al. Strategies for subtypes— dealing with the diversity of breast cancer: Highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2011[J]. Annals of Oncology, 2011, 22(8): 1736-1747.
[21] Lyman G H, Temin S, Edge S B, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update[J]. Journal of Clinical Oncology, 2014, 32(13): 1365-1383.
[22] Mamounas E P, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from national surgical adjuvant breast and bowel project protocol B-27[J]. Journal of Clinical Oncology, 2005, 23(12): 2694-2702.
[23] Hunt K K, Yi M, Mittendorf E A, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients[J]. Annals of Surgery, 2009, 250(4): 558-566.
[24] Kelly A M, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapysystematic review and meta analysis[J]. Academic Radiology, 2009, 16(5): 551-563.
[25] Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J]. Annals of Surgical Oncology, 2012, 19(10): 3177-3184.
[26] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study[J]. Lancet Oncology, 2013, 14(7): 609-618.
[27] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy final results from the prospective, German multiinstitutional SENTINA trial[C]. San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 4-8, 2012.
[28] Jagsi R, Jiang J, Momoh A O, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States[J]. Journal of Clinical Oncology, 2014, 32(9): 919-926.
[29] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
[30] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(14): 8418-8423.
[31] Yamamoto Y, Ibusuki M, Nakano M, et al. Clinical significance of basal-like subtype in triple-negative breast cancer[J]. Breast Cancer, 2009, 16(4): 260-267.
[32] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinicalbenefi t in breast cancer: The CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[33] Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the Gepar Quattro study[J]. Journal of Clinical Oncology, 2010, 28(12): 2024- 2031.
[34] Ollila D W, Berry D A, Cirrincione C, et al. Impact of neoadjuvant chemotherapy plus HER2- targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)[J]. Journal of Clinical Oncology, 2013, 31(S15): 501.
[35] Harbeck N. American Society of Clinical Oncology highlights 2013: Breast cancer and gynecological malignancies[J]. Future Oncology, 2013, 9(10): 1433-1436.
[36] Gianni L, Eiermann W, Semiglazov V, et al. Follow- up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT + H) followed by adjuvant H, versus CT alone, in patients with HER- 2 positive locally advanced breast cancer[J]. Journal of Clinical Oncology, 2013, 31(S15): 503.
[37] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone- receptor- positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 336(6): 520-529.
[38] O'Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab- resistant, advanced breast cancer (BOLERO-3)[J]. Journal of Clinical Oncology, 2013, 31(S15): 505.